Cullinan Therapeutics (CGEM) CEO sells shares to cover RSU tax bill

Rhea-AI Filing Summary

Cullinan Therapeutics reported that President and CEO Nadim Ahmed executed an open-market sale of 13,515 shares of common stock at $14.47 per share. According to the filing, the sale was made to cover personal income tax obligations upon vesting of restricted stock units. After this transaction, he directly owned 390,803 shares.

Insider Trade Summary

Net Seller: 13,515 shares ($195,562)

Net Sell 1 txn

Insider AHMED NADIM

Role President and CEO

Sold 13,515 shs ($196K)

Type	Security	Shares	Price	Value
Sale	Common Stock	13,515	$14.47	$196K

Holdings After Transaction: Common Stock — 390,803 shares (Direct)

Footnotes (1)

1. [object Object]

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

AHMED NADIM

(Last) (First) (Middle)

C/O CULLINAN THERAPEUTICS, INC.

ONE MAIN STREET, SUITE 1350

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cullinan Therapeutics, Inc. [ CGEM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		S(1)		13,515	D	$14.47	390,803	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Sale of shares to cover personal income tax obligations upon vesting of restricted stock units.

	/s/ Jacquelyn Sumer, Attorney-in-Fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cullinan Therapeutics (CGEM) report for Nadim Ahmed?

Cullinan Therapeutics reported that President and CEO Nadim Ahmed sold 13,515 shares of common stock. The sale was executed in the open market at a price of $14.47 per share, according to the Form 4 insider filing.

Why did CGEM CEO Nadim Ahmed sell 13,515 shares of stock?

The Form 4 states the sale was made to cover personal income tax obligations. These taxes arose in connection with the vesting of restricted stock units granted to Nadim Ahmed as part of his compensation package.

At what price were the Cullinan Therapeutics (CGEM) shares sold by the CEO?

The reported transaction shows an open-market sale price of $14.47 per share. Nadim Ahmed sold 13,515 shares of Cullinan Therapeutics common stock at this price as disclosed in the Form 4 filing.

How many Cullinan Therapeutics (CGEM) shares does Nadim Ahmed hold after this sale?

Following the reported transaction, Nadim Ahmed directly owns 390,803 shares of Cullinan Therapeutics common stock. This post-transaction holding figure is disclosed in the Form 4 and reflects his remaining direct ownership.

Is the CGEM CEO’s share sale described as a discretionary sale or tax-related?

The footnote explains the sale was to cover personal income tax obligations tied to restricted stock unit vesting. This indicates it was a tax-related sale rather than a purely discretionary open-market liquidation of his Cullinan Therapeutics holdings.

What type of security did Nadim Ahmed trade in the CGEM Form 4 filing?

The Form 4 identifies the security as common stock of Cullinan Therapeutics. The filing reports a single non-derivative transaction involving 13,515 common shares sold in the open market at $14.47 per share.